InspireMD, Inc. (NYSEAMERICAN: NSPR) Files An 8-K Other EventsItem 8.01 Other Events.
On November 28, 2018, InspireMD, Inc. announced that its CGuard™ Embolic Prevention System (EPS) has been granted regulatory approval by the Australian Therapeutic Goods Administration for commercial sale and reimbursement in Australia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press release dated November 28, 2018|
InspireMD, Inc. ExhibitEX-99.1 2 ex99-1.htm InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia Commercial Launch to Occur Immediately Tel Aviv,…To view the full exhibit click